Current Rheumatology Reports最新文献_第10页

Cannabidiol (CBD) in Rheumatic Diseases (Musculoskeletal Pain) 大麻二酚（CBD）在类风湿性疾病（肌肉骨骼疼痛）中的作用

IF 5 2区医学

Current Rheumatology Reports Pub Date : 2022-05-03 DOI: 10.1007/s11926-022-01077-3

K. Boehnke, W. Häuser, M. Fitzcharles

引用次数: 9

Detection and Monitoring of Interstitial Lung Disease in Patients with Systemic Sclerosis. 系统性硬化症患者间质性肺疾病的检测与监测

IF 5.7 2区医学

Current Rheumatology Reports Pub Date : 2022-05-01 DOI: 10.1007/s11926-022-01067-5

Surabhi Agarwal Khanna, John W Nance, Sally A Suliman

{"title":"Detection and Monitoring of Interstitial Lung Disease in Patients with Systemic Sclerosis.","authors":"Surabhi Agarwal Khanna, John W Nance, Sally A Suliman","doi":"10.1007/s11926-022-01067-5","DOIUrl":"10.1007/s11926-022-01067-5","url":null,"abstract":"Purpose of review: Interstitial lung disease (ILD) is a common manifestation of systemic sclerosis (SSc). We explore the importance of early detection, monitoring, and management of SSc-ILD.Recent findings: All patients with SSc are at risk of ILD and should be screened for ILD at diagnosis using a high-resolution computed tomography (HRCT) scan. Some patients with SSc-ILD develop a progressive phenotype characterized by worsening fibrosis on HRCT, decline in lung function, and early mortality. To evaluate progression and inform treatment decisions, regular monitoring is important and should include pulmonary function testing, evaluation of symptoms and quality of life, and, where indicated, repeat HRCT. Multidisciplinary discussion enables comprehensive evaluation of the available information and its implications for management. The first-line treatment for SSc-ILD is usually immunosuppression. The antifibrotic drug nintedanib has been approved for slowing lung function decline in patients with SSc-ILD. Optimal management of patients with SSc-ILD requires a multidisciplinary and patient-centered approach.","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399070/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44273769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cannabis for Rheumatic Disease Pain: a Review of Current Literature 大麻治疗类风湿性疾病疼痛的文献综述

IF 5 2区医学

Current Rheumatology Reports Pub Date : 2022-04-29 DOI: 10.1007/s11926-022-01065-7

W. B. Nowell, K. Gavigan, Stuart L. Silverman

引用次数: 9

Familial Mediterranean Fever: How to Interpret Genetic Results? How to Treat? A Quarter of a Century After the Association with the Mefv Gene 家族性地中海热:如何解释基因结果?如何治疗?在与Mefv基因联系的四分之一个世纪之后

IF 5 2区医学

Current Rheumatology Reports Pub Date : 2022-04-18 DOI: 10.1007/s11926-022-01073-7

E. D. Batu, Ozge Basaran, Y. Bilginer, S. Ozen

引用次数: 3

Update on Uric Acid and the Kidney 尿酸与肾脏最新进展

IF 5 2区医学

Current Rheumatology Reports Pub Date : 2022-04-14 DOI: 10.1007/s11926-022-01069-3

G. Ramos, D. Goldfarb

引用次数: 11

Update on Cutaneous Signs to Assist in the Diagnosis of Dermatomyositis 皮肤体征辅助诊断皮肌炎的最新进展

IF 5 2区医学

Current Rheumatology Reports Pub Date : 2022-04-11 DOI: 10.1007/s11926-022-01070-w

Ghida El-Banna, D. Fiorentino

引用次数: 2

Future of Low-Dose Computed Tomography and Dual-Energy Computed Tomography in Axial Spondyloarthritis 低剂量计算机断层扫描和双能计算机断层扫描在轴性脊柱炎中的应用前景

IF 5 2区医学

Current Rheumatology Reports Pub Date : 2022-04-09 DOI: 10.1007/s11926-022-01075-5

T. Diekhoff, K. Hermann, R. Lambert

引用次数: 5

The Microbiome in Osteoarthritis: a Narrative Review of Recent Human and Animal Model Literature 骨关节炎的微生物组：最近人类和动物模型文献的叙述性综述

IF 5 2区医学

Current Rheumatology Reports Pub Date : 2022-04-07 DOI: 10.1007/s11926-022-01066-6

C. Dunn, M. Jeffries

引用次数: 9

Axial Spondyloarthritis in Japan 日本的轴性脊柱炎

IF 5 2区医学

Current Rheumatology Reports Pub Date : 2022-04-05 DOI: 10.1007/s11926-022-01068-4

H. Kameda, M. Kishimoto, Shigeto Kobayashi, T. Tomita, A. Morita, M. Yamamura

引用次数: 1

Is There Still a Role of Plasma Exchange in the Current Management of ANCA-Associated Vasculitides? 血浆置换在当前anca相关血管粥样硬化的治疗中是否仍有作用?

IF 5 2区医学

Current Rheumatology Reports Pub Date : 2022-04-01 Epub Date: 2022-03-22 DOI: 10.1007/s11926-022-01064-8

Task Toyoda, Max Yates, Richard A Watts

{"title":"Is There Still a Role of Plasma Exchange in the Current Management of ANCA-Associated Vasculitides?","authors":"Task Toyoda, Max Yates, Richard A Watts","doi":"10.1007/s11926-022-01064-8","DOIUrl":"https://doi.org/10.1007/s11926-022-01064-8","url":null,"abstract":"Purpose of review: Plasma exchange (PLEX) is often recommended as an adjunctive therapy for patients with ANCA-associated vasculitis (AAV) in the setting of rapidly progressive glomerulonephritis or diffuse alveolar haemorrhage. Since ANCAs are pathogenic, it seems a reasonable and justified approach to remove them through therapeutic PLEX, as despite advances in immunosuppressive therapy regimens, AAV is associated with significant morbidity and death. However, the association between ANCA levels and mortality or disease activity is uncertain. In addition, any treatment must be judged on the potential risks and benefits of its use. Here, we summarise the current data on PLEX usage in patients with AAV.Recent findings: The largest randomised trial to date the Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis (PEXIVAS) study failed to show added benefit for PLEX on the prevention of death or end-stage renal failure (ESRF) for the management of patients with severe AAV. However, there is a possibility that PLEX delays dialysis dependence and ESRF in the early stages of the disease. Regardless of whether this is only for 3 to 12 months, this could be of clinical significance and a substantial improvement in patient's quality of life. Cost utility analysis and trials including patient-centred outcomes are required to evaluate the use of PLEX. Furthermore, ascertaining those at high risk of developing ESRF could help identify those who may benefit from PLEX the most, and further insights are required in setting of diffuse alveolar haemorrhage.","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":null,"pages":null},"PeriodicalIF":5.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9005426/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40311077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1